As the bridge between the organization and external stakeholders, Medical Affairs professionals require excellent communication skills. This eLearning course creates expertise in planning and delivering presentations in all formats to all audiences.
Pharmaceutical teams need a different way to approach working virtually. The secret isn’t adding more virtual calls, but unlocking the strategic power of virtual work. Download this white paper to see how your peers are achieving more, with fewer meetings.
MAPS offers a short video tutorial on Zoom/Teams best practices. Yes, it’s finally time to learn to use these tools well…
Three accomplished Medical Affairs executives representing different regions of the globe have helped build the inaugural Mentorship Program at MAPS will be discussing their personal stories, perspectives, and offer critical suggestions that will redefine and inspire a next generation view of Mentorship
Now is a critical time for Medical Affairs leaders to redefine their roles and boldly re-engage patients by employing a few key tactics learned from the past year.
This MAPS podcast with AlphaGroup of Medical Communications Companies explores areas of collaboration between Medical Affairs and HEOR groups.
Connectivity and digitization of medical device technologies can improve device functionality and benefit. However, the connection of medical devices to networks or the internet exposes them to increased cyber threats.
MAPS explores Health Economics and Outcomes Research (HEOR): Why a Medical Affairs organization needs an HEOR function and how to build this capability.
Listeners will understand how the Medical Affairs strategic planning process can drive decision making throughout the year.
The Medical Affairs Professional Society (MAPS) is honored to announce the inclusion of Janssen Pharmaceuticals, Inc. in the MAPS Industry Partnership Program (IPP), providing free MAPS membership and training resources for all Janssen Medical Affairs employees globally, as well as opportunities for Janssen leaders to collaborate with peers in other leading biopharmaceutical and medical technology organizations to set strategic direction for the Medical Affairs function.
“Janssen’s partnership with MAPS demonstrates both organizations’ commitment to excellence in Medical Affairs, from placing leaders in a position to influence the future of the profession, to optimizing the competencies of individual team members,” says Travis Hege, MAPS CEO.
Organizations involved in the MAPS IPP become part of a collaborative community of industry leaders and agents for progress in Medical Affairs. Program benefits include participation in regular Executive Consortium meetings for Chief Medical Officers and Global Medical Affairs Heads, priority invitations for senior leaders to participate on expert panels at MAPS Annual Meetings, and full access memberships to MAPS for all Medical Affairs employees in the organization company-wide. Membership also provides access to a community of peers as well as training resources including webinars, articles, best practices forums, eLearning modules, mentorship opportunities, and more.
Janssen joins existing MAPS Industry Partnership Program organizations Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly & Co., Lundbeck, Mallinckrodt, Otsuka, Pfizer, Sanofi, Teva and UCB.
“As biopharmaceutical companies seek to deliver new medicines to new patient populations, the role of Medical Affairs is becoming increasingly important. MAPS is excited to grow with our industry partners and with the Medical Affairs function as a whole,” says Hege. “Together we are expanding the capabilities of the function to drive better outcomes for organizations and for patients.”